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 The apolipoprotein A5 gene ( APOA5 ) is predominantly 
expressed in the liver and secreted into the blood where it 
resides on HDL and VLDL particles ( 1 ). Despite its very 
low levels in plasma, apoA5 appears to facilitate the in-
teraction between circulating lipoprotein particles and 
proteoglycans on the vascular wall with the subsequent ac-
tivation of proteoglycan-bound lipoprotein lipase ( 2–4 ). 
The  APOA5 -1131T>C single nucleotide polymorphism 
(SNP) has been reported to be functional and is associ-
ated with reduced apoA5 concentration or activity ( 5 ). In 
particular, the  APOA5 -1131C variant allele modulates the 
effects of dietary PUFA intake on fasting triglyceride lev-
els, lipoprotein particle size ( 6 ), and obesity ( 7 ) and PUFA-
 APOA5 interactions are specifi c for dietary   6 PUFAs. The 
fatty acid composition of serum phospholipids mirrors di-
etary fatty acid intake over previous weeks and also refl ects 
 Abstract  We determined the contribution of the combina-
tion of  FEN1 10154G>T with the most signifi cant associa-
tion in the analysis of plasma arachidonic acid (AA, 20:4  6) 
and the  APOA5 -1131T>C on phospholipid   6PUFA and 
coronary artery disease (CAD). Patients with CAD (n = 807, 
27–81 years of age) and healthy controls (n = 1123) were 
genotyped for  FEN1 10154G>T and  APOA5 -1131T>C. We 
found a signifi cant interaction between these two genes for 
CAD risk ( P = 0.007) adjusted for confounding factors. 
 APOA5 -1131C allele carriers had a higher CAD risk [odds 
ratio (OR):1.484, 95% confi dence interval (CI):1.31–1.96; 
 P = 0.005] compared with  APOA5 -1131TT individuals in the 
 FEN1 10154GG genotype group but not in the  FEN1 10154T 
allele group (OR:1.096, 95%CI:0.84–1.43;  P = 0.504). Sig-
nifi cant interactions between these two genes were also ob-
served for the AA proportion ( P = 0.04) and the ratio of AA/
linoleic acid (LA, 18:2  6) ( P = 0.004) in serum phospholip-
ids of controls. The  APOA5 -1131C allele was associated with 
lower AA ( P = 0.027) and AA/LA ( P = 0.014) only in controls 
carrying the  FEN1 10154T allele.  In conclusion, the inter-
action between these genes suggests that the  FEN1 10154T 
variant allele decreases AA and AA/LA in the serum phospho-
lipids of carriers of the  APOA5 -1131C allele, but contributes 
no signifi cant increase in CAD risk for this population sub-
set despite their increased triglylcerides and decreased 
apoA5. —Park, J. Y., J. K. Paik, O. Y. Kim, J. S. Chae, Y. Jang, 
and J. H. Lee.  Interactions between the  APOA5 -1131T>C 
and the  FEN1 10154G>T polymorphisms on   6 polyunsatu-
 This work was supported by the National Research Foundation, Ministry of 
Education, Science and Technology (Mid-career Researcher Program: 2010-
0015017, M10642120002-06N4212-00210 and C00048), Seoul, Korea, and 
Korea Health 21 R&D Projects, Ministry of Health & Welfare (A000385), 
Seoul, Korea. None of the authors have any confl icts of interest in relation to the 
materials presented in this paper. 
 Manuscript received 5 August 2010 and in revised form 27 August 2010. 
 Published, JLR Papers in Press, August 27, 2010 
 DOI 10.1194/jlr.M010330 
 Interactions between the  APOA5 -1131T>C and the 
 FEN1 10154G>T polymorphisms on   6 polyunsaturated 
fatty acids in serum phospholipids and coronary 
artery disease 
 Ju Yeon  Park, 1, * ,†  Jean Kyung  Paik, 1, * ,§  Oh Yoen  Kim, * ,§  Jey Sook  Chae, * ,§  Yangsoo  Jang , §,**,††,§§ 
and  Jong Ho  Lee 2, * ,†,§ 
 National Research Laboratory of Clinical Nutrigenetics/Nutrigenomics, Department of Food and 
Nutrition,* College of Human Ecology,  Yonsei University , Seoul,  Korea ; Department of Food and Nutrition, 
BK21 Project, † College of Human Ecology,  Yonsei University , Seoul,  Korea ; Yonsei University Research 
Institute of Science for Aging, §  Yonsei University , Seoul,  Korea ; and Cardiology Division,** Cardiovascular 
Genome Center; and Severance Medical Research institute, †† and Severance Biomedical Science
Research institute, §§   Yonsei University College of Medicine , Seoul,  Korea 
 Abbreviations: 8-epi-PGF 2   , 8-epi-prostaglandin F 2   ; AA, arachi-
donic acid; apo, apolipoprotein; BMI, body mass index; BP, blood pres-
sure; CAD, coronary artery idsease; CI, confi dence interval; CRP, 
C-reactive protein; D5D, delta 5 desaturase; DGLA, dihomo-  -linolenic 
acid; DM, diabetes mellitus; LA, linoleic acid; LLD, lipid-lowering drug; 
MDA, malondialdehyde; OR, odds ratio; ox-LDL, oxidized LDL; SNP, sin-
gle nucleotide polymorphism; TNF, tumor necrosis factor. 
 1 These two authors contributed equally to this work. 
 2 To whom correspondence should be addressed.  
  e-mail: jhleeb@yonsei.ac.kr 
 at Yonsei University M









3282 Journal of Lipid Research Volume 51, 2010
(TM-2654, A and D, Tokyo, Japan) after a 20 min rest. After a 
12 h fasting period, venous blood specimens were collected in 
EDTA-treated and plain tubes, centrifuged to produce plasma or 
serum, and stored at   70°C until analysis. 
 Genotyping of  FEN1 10154G>T and  APOA5 -1131T>C 
 Genomic DNA was extracted from 5 ml whole blood with a 
commercially available DNA isolation kit (WIZARDR Genomic 
DNA purifi cation kit, Promega, Madison, WI). Genotyping of 
 FEN1 10154G>T was performed with the Taqman assay (Applied 
Biosystems, Foster City, CA). Genotyping of  APOA5 -1131T>C was 
performed with SNP-IT TM assays and single primer extension 
technology (SNPstream 25K TM System, Orchid BioSciences, NJ). 
Colorimetric reactions were detected with an enzyme-linked im-
munosorbent assay (ELISA) reader, and the genotype was deter-
mined with QCReview TM software. 
 Serum lipid profi le and fasting glucose 
 Fasting total cholesterol and triglycerides were measured us-
ing commercially available kits on a Hitachi 7150 Autoanalyzer 
(Hitachi Ltd., Tokyo, Japan). After precipitation of serum chylo-
microns with dextran sulfate magnesium, the concentrations of 
LDL- and HDL-cholesterol in the supernatants were measured 
enzymatically. LDL cholesterol was indirectly estimated in partici-
pants with serum triglyceride concentrations less than 400 mg/ml 
with the Friedewald formula. Fasting glucose levels were measured 
with a glucose oxidase method and a Beckman Glucose Analyzer 
(Beckman Instruments, Irvine, CA). 
 Plasma apoA5 concentration 
 Plasma concentrations of apoA5 were measured with an 
enzyme immunoassay (Human Apolipoprotein A ELISA kit, 
Millipore, MO). The resulting color reaction was read at 450 nm 
on a Victor 2 plate reader (Perkin Elmer Life Sciences, Turka, 
Finland). 
 Fatty acid composition in serum phospholipids 
 The fatty acid composition in serum phospholipids was ana-
lyzed by gas chromatography (HP 7890A, Hewlett-Packard) with 
the modifi ed method of Folch et al. ( 20 ) and Lepage and Roy 
( 21 ). Individual fatty acids were identifi ed by comparing their 
retention times with those of standard fatty acid methyl esters 
and quantitated according to the peak areas relative to the total 
area (total fatty acid area was set at 100%). 
 Plasma ox-LDL and LDL particle size 
 Plasma oxidized LDL (ox-LDL) was measured using an en-
zyme immunoassay (Mercodia, Uppsala, Sweden). Particle size 
distribution of LDL (d1.019–1.063 g/ml) isolated by sequential 
fl otation ultracentrifugation was examined with a pore-gradient 
lipoprotein system (CBS Scientifi c, CA) with commercially avail-
able nondenaturing polyacrylamide slab gels containing a linear 
gradient of 2–16% acrylamide (Alamo Gels Inc., San Antonio, 
TX). Standards of latex beads (34 nm), thyroglobulin (17 nm), 
apoferritin (12.2 nm), and catalase (10.4 nm) were used to esti-
mate the relative migration rates of each band. Gels were scanned 
with a GS-800 Calibrated Imaging Densitometer (Bio-Rad, Graz, 
Austria). LDL particle size was calculated with reference to the 
relative migration value of the standards. 
 Urinary 8-epi-PGF 2   and plasma MDA 
 Urine was collected in polyethylene bottles containing 1% bu-
tylated hydroxytoluene after 12 h of fasting. The bottles were im-
mediately covered with aluminum foil and stored at –70°C until 
analysis. The compound 8-epi-prostaglandin F 2   (8-epi-PGF 2   ) 
endogenous fatty acid metabolism ( 8–11 ). However, an 
interaction of the  APOA5 -1131T>C SNP with the gene as-
sociated with intrinsic phospholipid PUFA metabolism has 
not been studied. 
 The key enzymes in PUFA metabolism are delta 5 desat-
urase (D5D) and delta 6 desaturase, which are encoded by 
the fatty acid desaturase 1 and 2 ( FADS1 and  FADS2 ) genes, 
respectively ( 12–14 ). These two genes are located in the 
desaturase gene cluster on chromosome 11 (11q12-13.1). 
A recent genome-wide association study for plasma PUFAs 
showed strong evidence for association with this region of 
chromosome 11 ( 15 ). The most signifi cant association was 
between the SNP rs174537 (fl ap endonuclease 1,  FEN1 
10154G>T) near  FADS1 and the analysis of arachidonic 
acid (AA, 20:4  6). AA is synthesized primarily in the liver 
and then mobilized to infl ammatory cells via blood lipo-
proteins ( 16 ). AA is the precursor of prostaglandins, leu-
kotrienes, and related compounds, all of which have 
important roles in infl ammation ( 17–19 ). Thus, the  FEN1 
10154G>T SNP may represent a candidate gene of impor-
tance in coronary artery disease (CAD). Therefore, we hy-
pothesized that genetic variation at the  APOA5 -1131 locus 
has an interactive effect with genetic variation at the  FEN1 
10154 locus on serum phospholipid   6 PUFA metabolism 
and CAD. Our aim was to determine the contribution 
of the combination of the  FEN1 10154G>T and  APOA5 
-1131T>C SNPs on serum phospholipid   6 PUFA metabo-
lism and CAD. 
 SUBJECTS AND METHODS 
 Study participants 
 Study participants were enrolled in a clinical study conducted 
by the Laboratory of Clinical Nutrigenetics/Nutrigenomics (pro-
ject#: 2010-0015017 and M10642120002-06N4212-00210) at 
Yonsei University. Study participants ranged in age from 27 to 81 
years old. Participants were recruited from the Cardiovascular 
Genome Center, Yonsei University Severance Hospital, Seoul, 
Korea. Control participant exclusion criteria were any diagnosis 
of vascular disease, diabetes mellitus (DM), cancer (clinically or 
by anamnesis), renal disease, liver disease, thyroid disease, and 
acute or chronic infl ammatory disease. No participant was taking 
any drugs or supplements. Inclusion criteria of patients with CAD 
were:  a ) angiographically confi rmed CAD with   50% occlusion 
of one or more major coronary arteries,  b ) myocardial infarction 
confi rmed according to the World Health Organization criteria for 
symptoms, enzyme elevation, or electrocardiographic changes,  c ) 
absence of nonatherogenic occlusion such as osteal stenosis and 
spasm,  d ) no orthopedic limitations or any diagnosis of DM, liver 
disease, renal disease, thyroid, or pituitary disease, and  e ) no 
acute or chronic infl ammatory disease. In total, 1,930 genetically 
unrelated Koreans were included; 807 CAD patients and 1,123 
control participants. Written informed consent was obtained 
from all participants, and the protocol was approved by the Insti-
tutional Review Board of Yonsei University. 
 Anthropometric parameters, BP, and blood collection 
 Body weight and height were measured unclothed and with-
out shoes in the morning for the calculation of body mass index 
(BMI) (kg/m 2 ). Blood pressure (BP) was measured in the left 
arm of seated patients with an automatic blood pressure monitor 
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blood pressure, CAD patients had lower concentrations of 
apoA5, total cholesterol, LDL cholesterol, HDL choles-
terol, and ox-LDL; higher concentrations of glucose, tri-
glyceride, CRP, MDA, and 8-epi-PGF 2   ; and smaller LDL 
particle size than controls. CAD patients had a lower pro-
portion of linoleic acid (LA, 18:2  6),   -linolenic acid 
(20:3  6), and eicosadienoic acid (20:2  6), a higher pro-
portion of dihomo-  -linolenic acid (DGLA, 20:3  6) and 
AA (20:4  6), and a higher ratio of AA/LA in serum phos-
pholipids than controls after adjusting for confounding 
factors ( Table 1 ). 
 When we subdivided patients with CAD into two groups, 
those not treated with LLD (n = 286) and those treated 
with LLD (n = 521), those not treated with LLD showed 
higher concentrations of total cholesterol (183.2 ± 2 vs. 
156.9 ± 2 mg/dl;  P < 0.001) and LDL cholesterol (106.8 ± 
2 vs. 82.0 ± 1 mg/dl;  P < 0.001) than patients treated with 
LLD. 
was measured with an enzyme immunoassay (BIOXYTECH uri-
nary 8-epi-PGF 2   
TM Assay kit, OXIS International Inc., OR). Uri-
nary creatinine was determined with the alkaline picrated (Jeffe) 
reaction. Urinary 8-epi-PGF 2   concentrations were expressed as 
pmol/mmol creatinine. Plasma malondialdehyde (MDA) was 
measured from thiobarbituric acid-reactive substances (TBARS 
Assay Kit, Zepto Metric Inc.). 
 Serum hs-CRP and TNF-  concentration 
 Serum hs-CRP (C-reactive protein) concentrations were mea-
sured with an Express + autoanalyzer (Chiron Diagnostics Co., 
Walpole, MA) with a commercially available, high-sensitivity 
CRP-Latex (II) X2 kit (Seiken Laboratories Ltd., Tokyo, Japan). 
Serum tumor necrosis factor-  (TNF-  ) concentrations were mea-
sured with a Bio-plex human cytokine panel (Bio-Rad, CA) 
using a Quantikine ELISA kit (Human TNF-  , R and D Systems, 
Minneapolis, MN). 
 Assessment of dietary intake 
 Dietary intake was assessed with a 24 h recall method and semi-
quantitative food frequency questionnaire. Dietary energy values 
and nutrient content were calculated using the Computer Aided 
Nutritional analysis program (CAN-pro 2.0. Korean Nutrition So-
ciety, Seoul, Korea). Total energy expenditure was calculated 
from activity patterns including basal metabolic rate, physical ac-
tivity over a 24-h period, and specifi c dynamic action of food. The 
base metabolic rate of each participant was calculated with the 
Harris-Benedict equation. 
 Statistical analysis 
 Statistical analyses were performed with SPSS version 12.0 for 
Windows (Statistical Package for the Social Sciences, SPSS Inc., 
Chicago, IL). Hardy-Weinberg Equilibrium and linkage disequi-
librium tests were examined using the Haploviewver 4.1 (Broad 
Inst., MA). The association of CAD with genotype was calculated 
using the odds ratio (OR) [95% Confi dence intervals (CIs)] for 
a chi-square test or logistic regression model after adjusting for 
confounding factors. The Student’s  t -test was used to compare 
parameters between the two groups. General linear model analy-
sis was also used to compare groups after adjusting for confound-
ing factors. We determined whether each variable was normally 
distributed before statistical testing and then logarithmic trans-
formation was performed on skewed variables. Frequency was 
tested with the chi-square test. Pearson correlation coeffi cients 
were used to examine relationships between variables. For de-
scriptive purposes, mean values are presented using untrans-
formed and unadjusted values. Results are the means ± SE or 
percentage. A two-tailed value of  P  < 0.05 was considered statisti-
cally signifi cant. 
 RESULTS 
 Characteristics of controls and patients with CAD 
 General characteristics of controls and patients with 
CAD are shown in  Table 1 . Patients with CAD had a lower 
prevalence of current smoking (20.1% vs. 24.4%;  P = 
0.025) and alcohol drinking (54.8% vs. 64.1%;  P < 0.001) 
than controls. Lipid-lowering drugs (LLD), antihyperten-
sive drugs, and antiplatelet drugs were used more fre-
quently in patients than in controls (64.4% vs. 0%,  P < 
0.001; 88.7% vs. 0%;  P < 0.001; 91.8% vs. 0%;  P < 0.001, 
respectively). After adjusting for sex, age, BMI, cigarette 
smoking, alcohol consumption, and systolic and diastolic 
 TABLE 1. Anthropometric and biochemical parameters of controls 
and patients with CAD 
Control (n = 1123) CAD (n = 807)
Male/Female, (%) 78.4/21.6 81.5/18.5
Age (yr) 56.1 ± 0.23 56.9 ± 0.34
BMI (kg/m 2 ) 24.1 ± 0.07 25.1 ± 0.10
Blood pressure (mm Hg)
Systolic 124.1 ± 0.46 127.2 ± 0.60
Diastolic 78.4 ± 0.32 77.3 ± 0.36
Fasting glucose (mg/dl) a 86.6 ± 0.24 88.8 ± 0.44*
Triglycerides (mg/dl) a 128.9 ± 2.22 147.3 ± 2.80***
ApoA5 (ng/ml) a 225.1 ± 3.55 197.4 ± 5.02***
Total-cholesterol (mg/dl) 195.5 ± 0.99 166.2 ± 1.38***
LDL-cholesterol (mg/dl) 117.9 ± 0.91 90.7 ± 1.25***
HDL-cholesterol (mg/dl) a 51.7 ± 0.42 45.5 ± 0.39***
LDL particle size (nm) 23.76 ± 0.02 23.47 ± 0.03***
TNF-  (pg/ml) a 5.38 ± 0.10 5.65 ± 0.43
hs-CRP (mg/dl) a 1.14 ± 0.06 2.08 ± 0.15***
Malondialdehyde (nmol/ml) a 9.18 ± 0.09 10.5 ± 0.17***
8-epi-PGF 2   (pg/mg 
creatinine) a 
1296.4 ± 18.2 1417.5 ± 27.0***
Ox-LDL (  /l) a 63.5 ± 0.75 59.5 ± 0.89***
FA composition (%) in serum 
PL
Total polyunsaturated   -6 FA 20.6 ± 0.19 20.6 ± 0.20
18:2(  -6) 12.9 ± 0.13 12.1 ± 0.13***
18:3(  -6) a 0.27 ± 0.01 0.24 ± 0.01
20:2(  -6) a 0.63 ± 0.05 0.36 ± 0.01***
20:3(  -6) 1.61 ± 0.03 1.86 ± 0.03***
20:4(  -6) 4.84 ± 0.07 5.72 ± 0.10***
Total polyunsaturated   -3 FA 5.39 ± 0.09 5.51 ± 0.12
18:3(  -3) a 0.16 ± 0.00 0.17 ± 0.01
20:3(  -3) a 0.09 ± 0.01 0.08 ± 0.00*
20:5(  -3) a 1.28 ± 0.03 1.44 ± 0.05
22:5(  -3) a 0.60 ± 0.01 0.60 ± 0.01
22:6(  -3) a 3.25 ± 0.06 3.21 ± 0.07
20:4(  -6)/20:3(  -6) 3.17 ± 0.04 3.21 ± 0.06*
AA/LA 0.38 ± 0.01 0.48 ± 0.01 ***. 
 APOA5 -1131T>C, n(%)
TT 566 (50.4) 363 (45.0)
TC 455 (40.5) 367 (45.5)
CC 102 (9.1) 77 (9.5)
 FEN1 10154 G>T, n(%)
GG 516 (45.9) 399 (49.4)
GT 494 (44.0) 330 (40.9)
TT 113 (10.1) 78 (9.7)
Mean ± SE.  P -values were tested with a paired  t -test. * P < 0.05, 
** P < 0.01, *** P < 0.001; adjusted for sex, age, BMI, cigarette smok-
ing, alcohol consumption, and systolic and diastolic BP.
 a  Logarithmic transformation.
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terol, MDA, ox-LDL, and DGLA than those with GG 
( Table 4 ). CAD patients carrying the  FEN1 10154T allele 
showed larger LDL particle size and a trend toward a de-
crease in 8-epi-PGF 2   . Minor T allele carriers of  FEN1 
10154G>T showed higher LA (18:2  6), lower AA (20:4  6), 
and lower ratio of AA/DGLA and AA/LA than GG partici-
pants in both the control and CAD groups. No genotype 
differences in apoA5, triglycerides, or   3 fatty acids in 
serum phospholipids were observed for  FEN 1 10154G>T 
(data not shown). 
 Genotype combinations for the two SNPs were con-
structed to evaluate interactions between the genes for se-
rum lipid profi les, LDL particle size, lipid peroxides, and 
  6 PUFA in serum phospholipids. Except for serum phos-
pholipid AA, no signifi cant interactions were observed be-
tween  APOA5 -1131T>C and  FEN1 10154G>T for these 
variables (data not shown). A signifi cant interaction be-
tween  APOA5 -1131T>C and  FEN1 10154G>T was observed 
for AA in serum phospholipids ( P = 0.04) and the AA/LA 
ratio ( P = 0.004) in healthy controls ( Fig. 1 ). Signifi cantly 
lower AA ( P = 0.029) was observed in controls with the 
minor C allele for  APOA5 -1131T>C who also carried the 
 FEN1 10154 minor T allele. Signifi cantly lower AA/LA ra-
tios ( P = 0.014) were observed in controls with the  APOA5 
-1131C minor allele who also carried the  FEN1 10154 mi-
nor T allele. In contrast, a trend toward an increase in the 
AA/LA ratio ( P = 0.085) was observed in controls with the 
 APOA5 -1131C minor allele who also carried the  FEN1 
10154 GG genotype. Although an interaction between the 
two genes for the 20:4(  6)/20:3(  6) ratio failed to reach 
statistical signifi cance ( P = 0.128), the  APOA5 -1131C al-
lele was associated with a higher 20:4(  6)/20:3(  6) ratio 
( P = 0.016) only in individuals carrying the  FEN1 10154T 
allele. The  FEN1 10154T allele was associated with lower 
20:3(  6) ( P = 0.005) only in individuals carrying the  APOA5 
-1131C allele ( Fig. 1 ). 
 Relation of serum phospholipid AA with apoA5, lipid 
peroxides, and TNF-  
 Pearson correlation analysis showed that the AA propor-
tion in serum phospholipids was positively correlated with 
ox-LDL ( r = 0.177,  P < 0.001), MDA ( r = 0.153,  P = 0.002), 
8-epi-PGF 2   ( r = 0.122,  P = 0.007), and TNF-  ( r = 0.187, 
 P < 0.001) in healthy controls. In addition, 8-epi-PGF 2   was 
positively correlated with TNF-  ( r = 0.094,  P = 0.037) and 
CRP ( r = 0.175,  P < 0.001) in healthy controls. In CAD 
 Distribution of  FEN1 10154G>T and  APOA5 -1131T>C 
polymorphisms 
 Genotype frequencies of  FEN1 10154G>T and  APOA5 
-1131T>C SNPs did not deviate from Hardy-Weinberg 
Equalibrium expectation. The genotype distribution and 
allele frequency of the  FEN1 10154G>T SNP between con-
trols and patients were comparable. As shown in  Table 1 , 
the genotype distribution of  APOA5 -1131T>C in controls 
and patients differed ( P = 0.058), and the -1131C allele was 
more frequent among CAD patients (55%) than controls 
(49.6%;  P = 0.019). Therefore, the presence of the  APOA5 
-1131C allele increased the OR of CAD risk after adjust-
ment for confounders (OR = 1.274; CI = 1.052-1.544, 
 P = 0.013). 
 Genotype combinations for the two SNPs were con-
structed to evaluate interaction between the genes and 
CAD risk.  Table 2 shows OR estimations of CAD risk for 
the  APOA5 -1131T>C polymorphism in stratifi ed analyses 
by  FEN1 10154G>T genotype. We found a statistically sig-
nifi cant interaction between  APOA5 -1131T>C and  FEN1 
10154G>T on CAD risk ( P = 0.007) after adjusting for 
confounders. The  APOA5 -1131C minor allele was associ-
ated with a 48.4% increase in CAD risk ( P = 0.005) in 
participants carrying the  FEN1 10154GG genotype rela-
tive to homozygous carriers of the wild-type alleles for 
each SNP ( FEN1 10154GG+ APOA5 -1131TT). In contrast, 
the  APOA5 -1131C minor allele was not associated with 
CAD risk ( P = 0.524) in participants carrying the  FEN1 
10154T allele when compared with the concomitant car-
rier status for the  FEN1 10154T allele and the  APOA5 
-1131TT genotype ( FEN1 10154T allele+ APOA5 -1131TT) 
( Table 2 ). 
 ApoA5, lipid profi les, LDL particle size, lipid peroxides, 
and   6 PUFA in serum phospholipids according to 
 APOA 5 -1131T>C and  FEN1 10154G>T polymorphisms 
 After adjusting for confounders, C allele carriers of 
 APOA5 -1131T>C showed lower apoA5, higher triglycer-
ide, lower HDL cholesterol, and smaller LDL particle size 
than TT participants in both the control and CAD group 
( Table 3 ). Controls with the  APOA 5 -1131C allele showed 
lower DGLA (20:3  6) in serum phospholipids. No geno-
type differences in levels of LDL, total cholesterol, lipid 
peroxides, and   3 fatty acids in serum phospholipids were 
observed for  APOA 5 -1131T>C (data not shown). Controls 
with the  FEN1 10154T allele showed lower total choles-
 TABLE 2. Risk of CAD depending on the  APOA5 –1131 T>C and  FEN1 10154 G>T polymorphisms 
 FEN1 10154 G>T
 APOA5  1131 T>C
GG GT+TT
 P  b for interaction between 
 APOA5 and  FEN1 Adjusted OR (95% CI)  P a Adjusted OR (95% CI)  P a 
TT 1 0.005 1 0.504 0.007
TC+CC 1.484 (1.13–1.96) 1.096 (0.84–1.43)
CI, Confi dence interval, OR, odds ratio.
 a  P -value for the genotype obtained from the corresponding logistic regression model after adjusting for age, 
BMI, sex, cigarette smoking, alcohol consumption, and systolic and diastolic BP.
 b  P for the interaction from the corresponding logistic regression model after adjusting for age, BMI, sex, 
cigarette smoking, alcohol consumption, and systolic and diastolic BP.
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role for apoA5 in VLDL assembly ( 3, 23 ) or triglyceride 
hydrolysis ( 24 ). Previous studies have shown interaction 
effects between dietary   6 PUFA and  APOA5 -1131T>C 
when determining fasting triglyceride, lipoprotein particle 
size ( 6 ), postprandial triglyceride ( 2, 25, 26 ), BMI, and 
obesity risk ( 7 ). Although PUFA levels in phospholipids 
are known to be determined by a combination of dietary 
intake and metabolic effi ciency ( 15, 27–29 ), an interac-
tion between  APOA5 -1131T>C and  FEN1 10154G>T poly-
morphisms on   6 PUFA metabolism and CAD has not 
been previously reported.  FEN1 10154G>T near  FADS1 was 
found to be the SNP with the most signifi cant association 
in the analysis of AA (20:4  6), the long-chain   6 deriva-
tive of LA (18:2  6), in a recent genome-wide association 
study of plasma PUFAs ( 15 ). 
 Martinelli et al. ( 30 ) showed that a higher ratio of AA/
LA is an independent risk factor for CAD, and a graded 
increase in CAD risk is related to the carrier status of 
 FADS haplotypes associated with a higher desaturase ac-
tivity. Conversely, a possible causality link between vascu-
lar disease and lower desaturase activity also has been 
suggested ( 31 ). However, exaggerated desaturation and 
elongation generally have been reported to characterize 
CAD patients and individuals with major risk factors for 
CAD ( 30, 32–35 ). In addition, AA in adipose tissue was 
patients, AA was negatively correlated with apoA5 ( r = 
  0.146,  P = 0.030) and positively correlated with 8-epi-
PGF 2   ( r = 0.126,  P = 0.018). 
 DISCUSSION 
 We found an interaction between  APOA5 -1131T>C and 
 FEN1 10154G>T for CAD risk. The interaction effect be-
tween these two genes revealed that carriers of the  APOA5 
-1131C allele, despite their increased triglycerides and de-
creased apoA5, were not associated with CAD risk when 
carrying the  FEN1 10154T variant allele as compared with 
participants homozygous for the  APOA5 -1131T allele. 
This circumstance may mask or reduce the risk estimation 
of CAD if the interaction between  APOA5 -1131T>C and 
 FEN1 10154G>T is not considered. This fi nding partly ex-
plains the highly controversial results regarding the asso-
ciation of the  APOA5 -1131C variant allele with CAD risk 
despite the general consistency regarding its relationship 
with higher triglyceride and lower apoA5 concentrations. 
 ApoA5 is an important regulator of triglyceride-rich li-
poprotein metabolism ( 22 ). In controls with the  APOA5 
-1131C allele, higher triglycerides, smaller LDL particle 
size, and lower levels of apoA5 and serum phospholipid 
DGLA (20:3  6) are consistent with the suggestion of a 
 TABLE 3. Associations of the  APOA5 -1131T>C genotypes with plasma apoA5, lipid profi les, 
and   6 PUFA in serum phospholipids 
Control (n = 1123) CAD (n = 807)
APOA5 TT
(n = 566)




APOA5 C allele 
(n = 444)
ApoA5 (ng/ml) a 238.2 ± 5.21 213.7 ± 4.78*** 213.1 ± 7.70 185.0 ± 6.50***
Triglyceride (mg/dl) a 118.3 ± 2.56 139.6 ± 3.58*** 136.8 ± 3.51 156.0 ± 4.17***
HDL-cholesterol (mg/dl) a 52.8 ± 0.59 50.7 ± 0.59** 46.2 ± 0.58 44.9 ± 0.52*
LDL particle size (nm) 23.8 ± 0.03 23.7 ± 0.03*** 23.6 ± 0.04 23.4 ± 0.04***
18:2(  6) 12.9 ± 0.17 12.8 ± 0.18 12.0 ± 0.18 12.3 ± 0.19
20:3(  6) 1.69 ± 0.04 1.53 ± 0.03** 1.89 ± 0.05 1.84 ± 0.04
20:4(  6) 4.95 ± 0.10 4.74 ± 0.10 5.65 ± 0.15 5.77 ± 0.13
20:4(  6)/20:3(  6) 3.11 ± 0.06 3.23 ± 0.06 3.11 ± 0.08 3.29 ± 0.08
AA/LA 0.39 ± 0.01 0.37 ± 0.01 0.48 ± 0.01 0.49 ± 0.01
Mean ± SE.  P -values were tested with a paired  t -test, * P < 0.05, ** P < 0.01, *** P < 0.001; adjusted for sex, age, 
BMI, cigarette smoking, alcohol consumption, and systolic and diastolic BP.
 a Logarithmic transformation.
 TABLE 4. Associations of the  FEN1 10154 G>T genotypes with serum lipids, lipid peroxides, 
and   6 PUFA in serum phospholipids 
Control (n = 1123) CAD (n = 807)
 FEN1 10154
GG (n = 516)
 FEN1 10154
T allele (n = 607)
 FEN1 10154 
GG n = 399)
 FEN1 10154
T allele (n = 408)
Total-cholesterol (mg/dl) 197.6 ± 1.48 193.6 ± 1.34* 164.4 ± 1.91 168.0 ± 1.99
LDL particle size (nm) 23.7 ± 0.03 23.8 ± 0.03 23.4 ± 0.03 23.5 ± 0.04**
Malondialdehyde (nmol/ml) a 9.41 ± 0.15 8.98 ± 0.11* 10.6 ± 0.27 10.4 ± 0.21
8-epi-PGF 2   (pg/mg creatinine) 
a 1316.4 ± 28.3 1279.2 ± 23.6 1458.7 ± 41.2 1377.9 ± 35.0
Ox-LDL (  /L) a 65.0 ± 1.13 62.2 ± 1.01* 58.2 ± 1.17 60.7 ± 1.33
18:2(  6) 12.4 ± 0.18 13.2 ± 0.17** 11.6 ± 0.18 12.7 ± 0.19***
20:3(  6) 1.67 ± 0.04 1.56 ± 0.03* 1.82 ± 0.04 1.91 ± 0.05
20:4(  6) 5.36 ± 0.11 4.46 ± 0.09*** 6.17 ± 0.15 5.22 ± 0.12***
20:4(  6)/20:3(  6) 3.33 ± 0.06 3.05 ± 0.06*** 3.52 ± 0.08 2.87 ± 0.07***
AA/LA 0.43 ± 0.01 0.34 ± 0.01*** 0.54 ± 0.01 0.42 ± 0.01***
Mean ± SE. P-values were tested with a paired  t -test, * P < 0.05, ** P < 0.01, *** P < 0.001 adjusted for sex, age, 
BMI, cigarette smoking, alcohol consumption, and systolic and diastolic BP.
 a  Logarithmic transformation.
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 AA, a precursor of eicosanoids including prostaglandins 
and leukotrienes, is liberated from the hydrolysis of the 
 sn -2 position of glycerophospholipids ( 38 ). Radical per-
oxidation of AA produces a family of prostaglandin F 2 -
isomers called F 2 -isoprostanes ( 39 ). One such F 2 -isoprostane 
is 8-epi-PGF 2   , a sensitive and independent risk marker for 
CAD ( 40–42 ) that is probably released into biological fl u-
ids through a phospholipase-mediated pathway and con-
sequently excreted in urine. Here, we found a positive 
correlation between serum phospholipid AA and urinary 
excretion of 8-epi-PGF 2   in both controls and CAD pa-
tients. In addition, serum phospholipid AA was positively 
correlated with ox-LDL, a strong predictor for CAD ( 43 ), 
as well as MDA and TNF-  in controls. Interestingly, we 
also found a positive relationship between 8-epi-PGF 2   , 
TNF-  , and CRP. These results support the previous sug-
gestion that decreased synthesis and thus, availability of AA, 
mitigates the infl ammatory response by altering AA me-
tabolism, for example, by decreasing eicosanoid levels ( 11 ). 
 Several points should be considered when interpreting 
our fi ndings. First, our study measured D5D activity rather 
than concentration. PUFA levels were also expressed as a 
percent of total FAs in serum phospholipids rather than 
an absolute concentration. Therefore, we could detect 
relative differences in PUFA levels and D5D activity but 
were unable to decipher the mechanisms, which depend 
on the absolute values. Second, our results share the gen-
eral limitations of other cross-sectional observational studies 
in that we evaluated association, not prospective predic-
tion. Finally, we specifi cally focused on a representative 
group of Korean adults aged 27–81 years. This selection 
was based on the knowledge that CAD is greatly infl uenced 
by genetic factors at younger ages. Our controls had nor-
mal fasting glucose levels (<100 mg/dl) and were not taking 
any medications or functional foods. Therefore, our data can-
not be generalized to other ethnic groups or other popula-
tions. Despite these limitations, we found an interaction 
found to be associated with acute myocardial infarction 
( 36, 37 ), and this association was not related to dietary 
intake of   6 PUFA including LA ( 37 ). In this study, CAD 
patients also showed higher AA and AA/LA in serum 
phospholipids, but there was no signifi cant difference in 
the proportion of energy intake derived from fat and 
PUFA intake between control and CAD groups. Further-
more, fat intake did not differ according to genotype 
combination in either controls or CAD patients. There-
fore, the difference in   6 PUFAs in serum phospholip-
ids between controls and CAD patients was shown not to 
be derived from dietary fat intake but may be due to in-
trinsic phospholipid metabolism. In part, not only AA, 
but also its precursors including LA and DGLA in phos-
pholipids, are known to be genetically determined ( 15, 
29 ). 
 An interaction effect between  APOA5 -1131T>C and 
 FEN1 10154G>T was also found in serum phospholipid AA 
and AA/LA in controls. In the  FEN1 10154GG genotype 
group,  APOA5 -1131C allele carriers showed higher activ-
ity of D5D (AA/DGLA) and a trend toward an increase in 
AA/LA. In contrast, in the  FEN1 10154T minor allele 
group, the  APOA5 -1131C allele was associated with a lower 
AA/LA ratio. The mechanism of this interaction cannot 
be determined from our experimental approach. How-
ever, the  FEN1 10154T allele is associated with higher LA 
and lower AA in plasma PUFA ( 15 ), suggesting that this 
variant allele may reduce D5D expression and the elonga-
tion-desaturation process of converting LA to AA. There-
fore, the interaction effect between the two genes may be 
partly due to lower activity of D5D in controls with the 
 FEN1 10154T variant allele who also carry the  APOA5 
-1131C allele, and the result may be lower DGLA. This may 
also partly explain our current observation that the lowest 
AA and AA/LA in serum phospholipids was found in con-
trols carrying minor alleles at both genes, despite their in-
creased serum triglyceride levels. 
 Fig.  1. Serum phospholipid arachidonic acid (AA, 20:4  6) and the ratio of 20:4  6/20:3  6 and 20:4  6/18:2  6 by  APOA5 -1131T>C and 
 FEN1 10154G>T genotype combination in healthy controls. Mean ± SE.  P for interaction was tested by multiple logistic regression analysis 
after adjusting for sex, age, BMI, cigarette smoking, alcohol consumption, and systolic and diastolic BP. 
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